Therapeutic perspectives on uricases for gout

Joint Bone Spine

Volumn 79, Issue 3, 2012, Pages 237-242

  Garay, Ricardo P ^a   El Gewely, M Raafat ^b   Labaune, Jean Pierre ^c   Richette, Pascal ^d,e  

^a Universite Paris Sud   (France)

^b UNIVERSITY OF TROMSØ   (Norway)

^c Sorbonne Paris Cité ^*  (Switzerland)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Gout; Hyperuricaemia; Pegloticase; Rasburicasel; Uricase

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; MACROGOL; METHYLPREDNISOLONE; PEGLOTICASE; PLACEBO; RASBURICASE; RECOMBINANT ENZYME; RECOMBINANT URATE OXIDASE; THEOPHYLLINE; URATE OXIDASE; URIC ACID; URICOZYME; VIDARABINE; WARFARIN; XANTHINE OXIDASE INHIBITOR;

ADULT; ANAPHYLAXIS; ANEMIA; ANTIBODY TITER; ANTIGENICITY; ARTHRALGIA; BRONCHOSPASM; CHILD; CHRONIC DISEASE; DRESS SYNDROME; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EUROPE; FEVER; FOOD AND DRUG ADMINISTRATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GOUT; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMOLYSIS; HUMAN; HYPERURICEMIA; KIDNEY FAILURE; METHEMOGLOBINEMIA; MUSCLE SPASM; NAUSEA; NEPHROLITHIASIS; NONHUMAN; OFF LABEL DRUG USE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; RISK; SHORT SURVEY; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

EID: 84860560534     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.01.004     Document Type: Short Survey

References (57)

1. Merriman T.R., Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine 2011, 7:35-40.
2. Oda M., Satta Y., Takenaka O., et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002, 19:640-653.
3. Doherty M. New insights into the epidemiology of gout. Rheumatol 2009, 48:ii2-ii8.
4. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
5. Annemans L., Spaepen E., Gaskin M., et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008, 67:960-966.
6. Jordan K.M., Cameron J.S., Snaith M., et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatol 2007, 46:1372-1374.
7. Perez-Ruiz F., Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. Arthritis Care Res 2007, 57:1324-1328.
8. Terkeltaub R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther 2009, 11:236-247.
9. London M., Hudson P.B. Uricolytic activity of purified uricase in two human beings. Science 1957, 125:937-938.
10. EMA. European Medicines Agency. Rapport européen public d'évaluation. Fasturtec. 2001. http://www.emeaeuropa.eu/.
11. Brière C., Richette P., Hoenen-Clavert V., et al. Efficacité et tolérance de la rasburicase (Fasturtec) chez des patients goutteux intolérants ou réfractaires à l'allopurinol. Rev Rhum 2006, 73:1033.
12. Richette P., Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheum 2006, 2:338-342.
13. Richette P., Brière C., Hoenen-Clavert V., et al. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007, 34:2093-2098.
14. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005, 20:431-433.
15. Moolenburgh J., Reinders M., Jansen T. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006, 25:749-752.
16. FDA. Food and Drug Administration. Label and approval history KRYSTEXXA BLA 125293 Savient Pharm. 2010; http://www.fda.gov/.
17. Sundy J.S., Baraf H.S.B., Yood R.A., et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients' refractory to conventional treatment. JAMA 2011, 306:711-720.
18. Sundy J.S., Becker M.A., Baraf H.S.B., et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment failure gout. Arthritis Rheum 2008, 58:2882-2891.
19. Sundy J.S., Ganson N.J., Kelly S.J., et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021-1028.
20. Baraf H.S.B., Matsumoto A.K., Maroli A.N., et al. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 2008, 58:3632-3634.
21. Dubost J.J., Mathieu S., Soubrier M. Traitement de la goutte. Rev Med Interne 2011, 10.1016/j.revmed.2011.02.007.
22. Patte C., Sakiroglu C., Ansoborlo S., et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol 2002, 13:789-795.
23. Pui C.H. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Seminars Hematol 2001, 38:13-21.
24. Rozenberg S.R.B., Dorent R., Koeger A.C., et al. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed 1995, 62:392-394.
25. Burns C.M., Wortmann R.L. Gout therapeutics: new drugs for an old disease. Lancet 2011, 377:165-177.
26. Kennedy L.D., Ajiboye V.O. Rasburicase for the prevention and treatment of hyperuricemia in tumour lysis syndrome. J Oncol Pharm Pract 2010, 16:205-213.
27. Cortes J., Moore J.O., Maziarz R.T., et al. Control of plasma uric acid in adults at risk for tumour lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone. Results of a multicenter Phase III study. J Clin Oncol 2010, 28:4207-4213.
28. Bertrand Y., Mechinaud F., Brethon B., et al. SFCE (Societe française de lutte contre les cancers et leucemies de l'enfant et de l'adolescent). Recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey. J Pediatr Hematol Oncol 2008, 30:267-271.
29. Coiffier B., Mounier N., Bologna S., et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'étude des lymphomes de l'adulte trial on rasburicase activity in adult lymphoma) study. J Clin Oncol 2003, 21:4402-4406.
30. Hill C.L., Lu T.Y., Cervelli M., et al. Failure of rasburicase therapy in recurrent acute gout with tophi. Int J Rheum Dis 2008, 11:315-317.
31. Altman K.I., Smull K., Barron E.S.G. A new method of the preparation of uricase and the effect of uricase on the blood uric acid levels of the chicken. Arch Biochem 1959, 21:158-164.
32. Zittoun R., Dauchy F., Teillaud C., et al. Le traitement des hyperuricémies en hématologie par l'urate-oxydase et l'allopurinol. Ann Med Int 1976, 127:479-485.
33. Davis S., Park Y.K., Abuchowski A., et al. Hypouricaemic effect of polyethylenglycol-modified urate oxidase. Lancet 1981, 318:281-283.
34. Schiavon O., Caliceti P., Ferruti P., et al. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). Il Farmaco 2000, 55:264-269.
35. Jevsevar S., Kunstelj M., Porekar V.G. PEGylation of therapeutic proteins. Biotechnol J 2010, 5:113-128.
36. Chua C.C., Greenberg M.L., Viau A.T., et al. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1988, 10:114-117.
37. Kelly S.J., Delnomdedieu M., Oliverio M.I., et al. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 2001, 12:1001-1009.
38. Hershfield MS, Kelly SJ, inventors. Urate oxidase. US Patent 7,056,713 B1, Duke University. USA 2006.
39. Sherman M.R., Saifer M.G.P., Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008, 60:59-68.
40. Ganson N., Kelly S., Scarlett E., et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006, 8:R12.
41. FDA. Food and Drug Administration. Briefing Document for the Arthritis Advisory Committee Meeting. Arthritis Drugs Advisory Committee. 2010;UCM165714. http://www.fda.gov/.
42. Hershfield M.S., Roberts L.J., Ganson N.J., et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci 2010, 107:14351-14356.
43. Anderson A, Singh JA. Pegloticase for chronic gout. Cochrane Database Syst Rev. 2010;CD008335.
44. 3SBio. 3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million. The Medical News: News-Medical. Net; 2010.
45. FDA. Food and Drug Administration. Krystexxa (pegloticase). Risk evaluation and mitigation strategy (REMS). 2010. http://www.fdagov/downloads.
46. Mayer M.D., Khosravan R., Vernillet L., et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective Inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005, 12:22-34.
47. Horowitz Z. Puricase, first new drug treatment approach for gout in 40 years, could potentially revolutionise treatment for some. Medical News Today. 2006; http://www.medicalnewstoday.com/.
48. Hande K.R., Noone R.M., Stone W.J. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.
49. Vidal. Zyloric. Dictionnaire Vidal. 2011:2581-2.
50. Cannella A.C., Mikuls T.R. Understanding treatments for gout. Am J Manag Care 2005, 11:S451-S458.
51. Reinders M.K., Jansen T.L. New advances in the treatment of gout: review of pegloticase. Ther Clin Risk Manag 2010, 6:543-550.
52. Ueng S. Rasburicase (Elitek): a novel agent for tumour lysis syndrome. Proc Bayl Univ Med Cent 2005, 18:275-279.
53. Yim B.T., Sims-McCallum R.P., Chong P.H. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003, 37:1047-1054.
54. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnology annual review 2008, 191-202. Elsevier. M. Raafat El-Gewely (Ed.).
55. El-Gewely M.R., Fenton C., Kjeldsen E., et al. Site-specific encyclopedia of life sciences 2005, Nature Publishing Group & Wiley, p. 1-12.
56. Vidal. Fasturtec. Dictionnaire Vidal 2011;87:826-7.
57. Comer B. Savient focuses on reimbursement for Krystexxa launch. Medical Marketing & Media. 2011.